Healthcare · Drug Manufacturers - Specialty & Generic
Made onAug 23, 2026
Price at call$10.00
6-month call Bear -5.0%
Target by Feb 2027$9.50
Great value below$8.50
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change-5.0% to $9.50
Predicted High$9.98in 2 weeks
Predicted Low$9.50at 6 months
Max Drawdown (predicted)-5.0%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Aug 23, 2026 1:29 pm
Bear
HLN trends lower to
$9.50
(-5.0% from $10.00)
by Feb 2027.
decay
ThesisHLN is a low-beta defensive trading slightly above composite fair value with no near-term catalysts. Expect mild mean reversion toward the $9.14-$9.48 fair value band, tempered by risk-on regime support and DCF anchor near current price.
Invalidated ifBreak above $10.75 on volume or drop below $8.90 would invalidate the slow-drift-lower thesis
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $10.00 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Aug 23, 2026
—
$10.00at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Sep 6, 2026
$9.51–$10.49typical range · internal point $9.98
—
±4.9%
6/10
Low vol drift, risk-on regime keeps price stable
What actually happened:
closed $9.60
on Sep 4, 2026 = -4.0% vs the call
(predicted -0.2%)
· direction HIT
(called flat, was flat)
· off by 3.8 pp
· accuracy 9/10
· typical range ±4.9%:
inside the band
· S&P +0.6%
over the same window — beat it
1 month
Sep 23, 2026
$9.30–$10.70typical range · internal point $9.90
—
±7.0%
6/10
Mild gravity toward fair value, no catalyst
What actually happened:
closed $9.25
on Sep 22, 2026 = -7.5% vs the call
(predicted -1.0%)
· direction MISS
(called flat, was down)
· off by 6.5 pp
· accuracy 4/10
· typical range ±7.0%:
OUTSIDE the band
· S&P +1.2%
over the same window — beat it
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$10.15
(+1.5%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.
All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.
Value anchors (from deep analysis)
Price at call
$10.00
Composite fair value
$9.48
Signal-adjusted fair value
$9.14
DCF fair value
$10.25
Anchored-PE fair value
$11.01
Buy-below (value lens)
$8.50
Value net score
-37
Value confidence
7 / 10
Quality net score
+48
Memo confidence
7 / 10
Deserved value (base)
—
Quality tilt
—
Deserved value (used)
—
Coherence (value × quality)
—
Price behaviour (trailing — shapes the realism line)